Yasserged

GU Medical Oncologist @hopkinskimmel
Irish Trained Medical Oncologist
Former GU Oncology Fellow @MSKCC
Views are my own....

[OncLive.com @OncLive]

First-line therapy in RCC is a strategic decision that shapes the entire patient journey. Elizabeth Plimack, MD, MS, FASCO, Sundhar Ramalingam, MD, and Yasser Ged, MD, break it down in this 7-episode OncLive Insights series.

Watch now: https://t.co/JhFhifkPnb

#RenalCellCarcinoma #KidneyCancer #Oncology @ERPlimackMD @FoxChaseCancer @MdSundhar @DukeCancer @yasserged @hopkinskimmel

[UroToday.com @urotoday]

First-in-human study of [111In] XYIMSR-01 SPECT/CT, a novel carbonic anhydrase IX small molecule in patients with metastatic clear cell #RCC. Presentation by Yasser Ged, MBBS @HopkinsMedicine. #ASCO26 written coverage by @RKSayyid @UAUrology > https://t.co/Myqa2cfnwx @ASCO

[nirm @nirmishsingla]

Looking forward to a great line-up with GU onc experts from @brady_urology @hopkinskimmel @HopkinsMedicine @sibleyonline featuring @yasserged @CathyHandy @JCensits @akfsurgeon & Mohit Narang. Dinner and great networking opportunity. Thank you @MJHLifeSciences @OncLive !

[Dra. María Natalia Gandur Quiroga @nataliagandur]

💫🌟New Review on Testicular Germ Cell Tumors! 🌟💫
@nirmishsingla @AdityaBagrodia 
Dr #EzraBaraban @yalepathology @CDFankhauser @yasserged @JAMA_current @OncoAlert

💡 Key Insights:
🧬 Epidemiology & Risk Factors
🔹 Most common solid malignancy in men aged 15-40
🔹 ~10,000 cases annually in the U.S.
🔹 Risk factors: Cryptorchidism, family history, infertility, cannabis use, Klinefelter syndrome

🩺 Clinical Presentation & Diagnosis
🔹 Painless testicular mass is the most common symptom
🔹 Diagnosis: Scrotal ultrasound + tumor markers (AFP, β-hCG, LDH)

📊 Staging & Treatment
🔹 Stage I (70-75%): Orchiectomy + surveillance or adjuvant therapy 🏥
🔹 Stage II (20%): Lymph node involvement, treated with chemo, RPLND, or RT
🔹 Stage III (10%): Distant metastases → BEP/EP/VIP chemotherapy 💉

🎯 Survival & Long-term Effects
🔹 5-year survival rates: 99% (Stage I), 92% (Stage II), 85% (Stage III)
🔹 Long-term effects: Cardiovascular disease, secondary malignancies, infertility, hypogonadism, psychosocial impact

🧪 Emerging Biomarkers & Future Directions
🔹 miR-371a-3p: High sensitivity (91%) & specificity (94%) for early detection
🔹 Research is ongoing to refine risk stratification & de-escalate treatment
@UCSD_Urology @UCSDCancer @UCSDHealth @DrRanaMcKay @MadamSurgeonMD @cjkane10 @endourologyucsd
@JohnsHopkinsUni1
#OncoUrology #TesticularCancer #UroOncology #OncoTwitter #CancerResearch #MedicalOncology https://t.co/5GJxRea7ZO

[KaelinLab @kaelin_lab]

We report a new role for HIF in the regulation of endogenous retroviruses! It was a big collaborative effort to explore the HIF-mediated transcription, expression, and HLA presentation of ERVs in kidney cancer and leveraging them for immunotherapy

https://t.co/0Qpox9xWG2

[Gabriel Malouf @GabrielMalouf]

Our new study in JITC introduces a dual ERV-based stratification system for predicting immunotherapy efficacy in metastatic ccRCC patients. The model outperforms traditional transcriptomic signatures, offering enhanced precision for ICI treatment outcomes. @jitcancer 🙏Xiaofan Lu

[Ardit Feinaj, MD @FeinajArdit]

It’s an honor to present my poster at #ASCOGU. Sharing our findings on the impact of Area Deprivation Index on Immunotherapy outcomes in mRCC. Stop by poster D13 to discuss! #CancerResearch #ASCOGU25

[Hoosier Cancer @hoosiercancer]

Congratulations, Dr. Noah Hahn of @hopkinskimmel and all co-authors on presentation of ADAPT-BLADDER (HCRN-GU16-243) Cohort 4 results at #GU25.

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Ab#437 @ASCO #GU25 by @VincentWenxinXu👉 https://t.co/uiBniVraFJ👉post-hoc analysis of CheckMate214 #kidneycancer👉⬆️KIM-1 associated w/⬇️OS & KIM-1 reduction correlates w/⬆️ Ipi+Nivo efficacy👇 @OncoAlert @urotoday @Uromigos @KidneyCancer @kidneycan

[Miguel Zugman, MD @mzugman]

1/7 Pleased to share updated OS results from the #TIVO-3 study (NCT02627963), previously presented at #ESMO24. Our analysis focused on outcomes in patients with #ccRCC who had received prior treatment with a checkpoint inhibitor (CPI) - representing 26% of the trial population.

[Katy Beckermann @katy_beckermann]

🚨 New AI Tool for Immunotherapy Prediction! 🧠💊

A deep learning model predicts response to ICI in advanced NSCLC using H&E pathology slides! 🏥🔬

✅ Outperforms biomarkers like PD-L1 & TMB
✅ May improve selection for immunotherapy
✅ Hope to see in other tumor types!

[Sid Sadler @Sid423]

Coming from a patient point of view this is big stuff coming from @DanaFarber @YaleCancer @BraunMDPhD and many others!

[Yasserged @yasserged]

@nirmishsingla @JAMA_current @DrNDisis @JAMAOnc @AdityaBagrodia @CDFankhauser @HopkinsMedicine @brady_urology @AmerUrological @UroOnc @Uroweb @TestesCancer @TCSociety Honored to contribute to this Review with outstanding co-authors @nirmishsingla @AdityaBagrodia @CDFankhauser Ezra Baraban

[Yasserged @yasserged]

Our paper on IO combinations in metastatic translocation RCC is now online. Great collaborative work and addition to treatment outcomes in this rare entity. https://t.co/Gyk6VOxsA0 @nirmishsingla @montypal @KotechaMD @MattZibelman

[nirm @nirmishsingla]

Special thanks to Drs. Steven Schenkel & Kristin Walter @JAMA_current and @DrNDisis @JAMAOnc for the unique opportunity, & to coauthors @AdityaBagrodia @CDFankhauser @yasserged Ezra Baraban! @HopkinsMedicine @brady_urology @AmerUrological @UroOnc @Uroweb @TestesCancer @TCSociety

[Benjamin L Maughan @maughanonc]

Lots to learn from this and other ongoing trials in papillary kidney cancer. S1500 and others show us that it’s possible — please consider this trial for all your patients with this disease.

[nirm @nirmishsingla]

Special shout out to co-surgeons @YWLum @wrburnsmd @hopkinssurgery and med onc @yasserged @hopkinskimmel So fortunate to be part of the A-team for our patients @HopkinsMedicine! Great production by @brady_urology @HopkinsMedNews highlighting Chris’s story @TestesCancer @TCSociety

[KidneyCAN @kidneycan]

Can’t miss! The @OncJournal #KCRS24 abstract supplement is out!

🔗 https://t.co/NciWDV02X6

#KidneyCancer #RCC #AcceleratingCures

@OncoAlert @DrChoueiri @HHammersMD @montypal @DrRanaMcKay @arihakimi @DrYukselUrun

[Toni Choueiri, MD @DrChoueiri]

#TiNivo2 results are out —adding PD1 inhibitor nivolumab simply does not help after rechallenge /progression on prior immunotherapy. Time to follow level 1 evidence! @PRNews @TargetedOnc @OncLive @kidneycan @KidneyCancer @Uromigos @OncBrothers —implications beyond renal cancer ? 2nd (-) trial after #CONTACT3

https://t.co/T2em3JOsRb

@DanaFarber_GU

[Yasserged @yasserged]

Our paper on liver TACE and immunotherapy in RCC is now online. Great job by Jeffrey Schneider @MarkowskiGUOnc
@drchristosMD https://t.co/SFmyTxCWXb via @https://twitter.com/AmericanJIR